NO920503L - Potensiering av antireaktiv-antiastmatisk effekt av inhalerte loekke diuretika ved inhalerte ikke-stereoidiske anti-inflammatoriske medikamenter - Google Patents

Potensiering av antireaktiv-antiastmatisk effekt av inhalerte loekke diuretika ved inhalerte ikke-stereoidiske anti-inflammatoriske medikamenter

Info

Publication number
NO920503L
NO920503L NO92920503A NO920503A NO920503L NO 920503 L NO920503 L NO 920503L NO 92920503 A NO92920503 A NO 92920503A NO 920503 A NO920503 A NO 920503A NO 920503 L NO920503 L NO 920503L
Authority
NO
Norway
Prior art keywords
inhaled
stereoidic
antiastmatic
antireactive
potentization
Prior art date
Application number
NO92920503A
Other languages
English (en)
Norwegian (no)
Other versions
NO920503D0 (no
Inventor
Sebastiano Bianco
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO920503D0 publication Critical patent/NO920503D0/no
Publication of NO920503L publication Critical patent/NO920503L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/618Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A61K31/621Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate having the hydroxy group in position 2 esterified, e.g. benorylate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO92920503A 1991-02-09 1992-02-07 Potensiering av antireaktiv-antiastmatisk effekt av inhalerte loekke diuretika ved inhalerte ikke-stereoidiske anti-inflammatoriske medikamenter NO920503L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP91101817 1991-02-09

Publications (2)

Publication Number Publication Date
NO920503D0 NO920503D0 (no) 1992-02-07
NO920503L true NO920503L (no) 1992-08-10

Family

ID=8206392

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92920503A NO920503L (no) 1991-02-09 1992-02-07 Potensiering av antireaktiv-antiastmatisk effekt av inhalerte loekke diuretika ved inhalerte ikke-stereoidiske anti-inflammatoriske medikamenter

Country Status (15)

Country Link
US (2) US5366967A (pt)
EP (1) EP0499142A3 (pt)
JP (1) JPH0680587A (pt)
KR (1) KR920016093A (pt)
AU (1) AU652798B2 (pt)
BR (1) BR9200430A (pt)
CA (1) CA2060954A1 (pt)
CS (1) CS35392A3 (pt)
HU (1) HU209609B (pt)
IE (1) IE920426A1 (pt)
IL (1) IL100897A0 (pt)
MX (1) MX9200570A (pt)
NO (1) NO920503L (pt)
NZ (1) NZ241541A (pt)
ZA (1) ZA92891B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499143B1 (en) * 1991-02-09 1999-05-06 B.S.D. BIO SCIENCE DEVELOPMENT SNC Di OMINI C. & ZUCCARI G. Anti-reactive anti-asthmatic activity of acetylsalicylic acid by inhalation
HU219899B (hu) 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Inhalálóberendezés flutikaszon-propionát adagolására mért dózisban
TR199701170T1 (xx) 1995-04-14 1998-02-21 Glaxo Wellcome Inc. Beklometazon dipropionat i�in �l��lm�� doz inhaleri.
HU219900B (hu) 1995-04-14 2001-09-28 Glaxo Wellcome Inc. Mért dózist adagoló inhalálóberendezés
TR199701169T1 (xx) * 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Salmeterol i�in �l��lm�� doz inhaleri.
DE10034802A1 (de) * 2000-07-18 2002-01-31 Bayer Ag Stabile Salze von O-Acetylsalicylsäure mit basischen Aminosäuren
US7028990B2 (en) * 2001-05-11 2006-04-18 Ray Robert Shorey Temporary rooftop and stairway safety rail system
DE10223932A1 (de) * 2002-05-29 2003-12-18 Rudolf Wank Verwendung von Diuretika zur Behandlung von Schwellungen
DE102005025283A1 (de) * 2005-06-02 2006-12-07 Bayer Healthcare Ag Stabiler Wirkstoffkomplex von Salzen der o-Acetylsalicylsäure mit basischen Aminosäuren und Glycin
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
AU2013388034B2 (en) 2013-04-30 2019-08-15 Aspeya US Inc. Dry powder formulations and methods of use
CN112656780A (zh) 2014-02-20 2021-04-16 奥迪托皮克股份有限公司 用于吸入的干粉制剂
WO2017058370A1 (en) * 2015-09-30 2017-04-06 Rutgers, The State University Of New Jersey Carbonic anhydrase enzymes for regulating mast cell hematopoiesis and type 2 inflammation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888343A (en) * 1986-09-15 1989-12-19 Bristol-Myers Company Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
JPH0720862B2 (ja) * 1989-01-27 1995-03-08 ヘキスト・アクチエンゲゼルシヤフト 吸入用喘息治療剤
DE3907414A1 (de) * 1989-03-08 1990-09-13 Hoechst Ag Die anwendung inhalierter schleifendiuretika zur behandlung von allergen-induzierten nasalen reaktionen
DE4010536A1 (de) * 1990-04-02 1991-10-10 Boehringer Mannheim Gmbh Pharmazeutische waessrige loesung von 4-(2-(benzolsulfonylamino)-ethyl)-phenoxyessigsaeure

Also Published As

Publication number Publication date
IE920426A1 (en) 1992-08-12
AU1077092A (en) 1992-08-13
ZA92891B (en) 1992-12-30
EP0499142A2 (en) 1992-08-19
HUT60438A (en) 1992-09-28
US5750559A (en) 1998-05-12
EP0499142A3 (en) 1993-05-05
JPH0680587A (ja) 1994-03-22
NZ241541A (en) 1996-05-28
MX9200570A (es) 1994-07-29
IL100897A0 (en) 1992-11-15
BR9200430A (pt) 1992-10-13
HU209609B (en) 1994-09-28
CA2060954A1 (en) 1992-08-10
US5366967A (en) 1994-11-22
HU9200390D0 (en) 1992-04-28
AU652798B2 (en) 1994-09-08
NO920503D0 (no) 1992-02-07
CS35392A3 (en) 1992-08-12
KR920016093A (ko) 1992-09-24

Similar Documents

Publication Publication Date Title
NO920503D0 (no) Potensiering av antireaktiv-antiastmatisk effekt av inhalerte loekke diuretika ved inhalerte ikke-stereoidiske anti-inflammatoriske medikamenter
FI934971A0 (fi) Anlaeggning foer foerbraenning av spraengaemnen
NO924461D0 (no) Dipyridamol for behandling av proliferaktive sykdommer
NO176796C (no) Analogifremgangsmåte ved fremstilling av terapeutisk aktive triazolderivater
NO923526L (no) Fremgangsmaate for fremstilling av nafta
FI935803A0 (fi) Nedbrytning av organiska foereningar
NO953244L (no) Derivater av cyklodepeptid PF 1022
NO921777D0 (no) Fremgangsmaate for fremstilling av isoparaffiner
FI933502L (fi) Oxidation av titantetraklorid
FI935135A0 (fi) Foerfarande foer rening av TiO2-malm
DE69321109D1 (de) Herstellung von trifluorvinylethern
KR950701894A (ko) 하이드로 플루오로 알칸 제조 방법(production of hydrofluoroalkanes)
NO940190D0 (no) Anvendelse av x-ketoglutarat
NO952949D0 (no) Forlöpere av anti-inflamatoriske 3-acyl-2-oksindol-1-karboksamider
ITMI920605A1 (it) Associazioni di composti ad attivita' antivirale
NO923728D0 (no) Regioselektiv syntese av 1,5-diarylpyrazol-antiinflammatoriske midler
NO951808D0 (no) Fremgangsmåte ved fremstilling av enatiomert rene triazolylbenzotriazoler
NO930459D0 (no) Fremgangsmaate for fremstilling av plateformede konstruksjonselemente
NO912668L (no) Forskaling for bruk ved fremstilling av langsgaaende konstruksjoner
SE9201829D0 (sv) "atracta-sign" framstaellning av skyltstommar
FIU920385U0 (fi) Kombination av stordiaprojektor och projektorplatta
FI428U1 (fi) Verktyg foer formning av haestsko
SE9303498D0 (sv) Brandförvaring av gasol-tuber-flaskor "BRANDTUVEN"
KR940004232U (ko) 가변 축전기의 구조
FI950476A0 (fi) Foerbaettrande av stabiliteten av staevportens visir i fartyg